未登录

B

Brian Dymock

National University of Singapore

H指数:39

被引数:5,264

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

o-Vanillin binds covalently to MAL/TIRAP Lys-210 but independently inhibits TLR2

JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY

IF5.4

2024-02-282

OAAI

First-in-class orally active pharmacological inhibitors of TRPV6 for the treatment of advanced prostate cancer

MOLECULAR CANCER THERAPEUTICS

IF5.5

2023-12-010

PRE

First-in-class TRPV6 inhibitors for the treatment of prostate cancer

CANCER RESEARCH

IF16.6

2023-06-020

PRE

Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor

发现有效的组蛋白去乙酰化酶 (HDAC) 3/6选择性双重抑制剂

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

IF5.9

2019-12-0119

OAAI

Intranasal administration of a stapled relaxin-3 mimetic has anxiolytic- and antidepressant-like activity in rats

BRITISH JOURNAL OF PHARMACOLOGY

IF7.7

2019-09-1118

OAAI

A Small Molecule Targeting the Transmembrane Domain of Death Receptor p75NTR Induces Melanoma Cell Death and Reduces Tumor Growth

CELL CHEMICAL BIOLOGY

IF7.2

2018-12-0120

OAAI

Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

IF5.9

2018-10-0140

PREAI

SAHA and cisplatin sensitize gastric cancer cells to doxorubicin by induction of DNA damage, apoptosis and perturbation of AMPK-mTOR signalling

EXPERIMENTAL CELL RESEARCH

IF3.5

2018-09-0121

PREAI

Discovery of the cancer cell selective dual acting anti-cancer agent (Z)-2-(1H-indol-3-yl)-3-(isoquinolin-5-yl)acrylonitrile (A131)

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

IF5.9

2018-08-0114

PREAI

Dual blockade of the lipid kinase PIP4Ks and mitotic pathways leads to cancer-selective lethality

NATURE COMMUNICATIONS

IF15.7

2017-12-1967

OAAI

Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2017-10-1090

PREAI

Towards Selective Mycobacterial ClpP1P2 Inhibitors with Reduced Activity against the Human Proteasome

对人类蛋白酶体活性降低的选择性分枝杆菌ClpP1P2抑制剂

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2017-05-0127

OAAI

Bortezomib Warhead-Switch Confers Dual Activity against Mycobacterial Caseinolytic Protease and Proteasome and Selectivity against Human Proteasome

硼替佐米弹头开关赋予对分枝杆菌酪蛋白分解蛋白酶和蛋白酶体的双重活性和对人蛋白酶体的选择性

FRONTIERS IN MICROBIOLOGY

IF4.5

2017-04-2722

OAAI

A novel slow-releasing hydrogen sulfide donor, FW1256, exerts anti-inflammatory effects in mouse macrophages and in vivo

PHARMACOLOGICAL RESEARCH

IF10.5

2016-11-0160

PREAI

Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2016-09-0893

PREAI

Fragment-Based Whole Cell Screen Delivers Hits against M-tuberculosis and Non-tuberculous Mycobacteria

FRONTIERS IN MICROBIOLOGY

IF4.5

2016-09-0721

OAAI

The rise of epigenetic drug discovery

FUTURE MEDICINAL CHEMISTRY

IF3.4

2016-09-075

OAAI

Recently discovered EZH2 and EHMT2 (G9a) inhibitors

最近发现的EZH2和EHMT2 (G9a) 抑制剂

FUTURE MEDICINAL CHEMISTRY

IF3.4

2016-08-2225

PREAI

Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

IF5.9

2016-08-0119

OAAI

Overcoming Chloroquine Resistance in Malaria: Design, Synthesis, and Structure-Activity Relationships of Novel Hybrid Compounds

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2016-05-0116

OA